PDCD1 and neoplasm: Nowadays, numerous biomarkers, including tumor mutation burden (TMB), PD-L1 expression, microsatellite instability (MSI), and Epstein-Barr virus infection status, have been proposed to predict responsiveness to PD-1 and PD-L1 inhibitors [11,12].